无特定分子谱型子宫内膜癌分子分层面临的挑战
该系统综述与Meta分析检索截至2024年12月,纳入19项观察性研究,评估ProMisE分类未涵盖的分子改变在子宫内膜癌及NSMP亚组的预后价值。L1CAM过表达和ER缺失在总体人群和NSMP亚组均为不利预后因素,ARID1A突变的不良预后影响仅限于NSMP亚组。
要点
- L1CAM过表达在总体人群PFS HR 3.44,NSMP亚组PFS HR 3.34。
- ER缺失在总体人群PFS HR 3.13,NSMP亚组PFS HR 3.14。
- ARID1A突变不良预后仅见于NSMP亚组,PFS HR 2.35。
核心结论
- ER缺失和L1CAM过表达可能作为NSMP亚组的预后标志物,支持更个体化的辅助治疗策略。
- 需进一步研究以明确ARID1A等其他改变在NSMP肿瘤中的预后作用。
研究设计与样本
- 系统综述与Meta分析,按PRISMA指南进行,检索PubMed、Scopus和Web of Science截至2024年12月。
- 纳入19项研究:17项回顾性、2项前瞻性,均为观察性设计,报告风险比(HR)。
- 主要结局为无进展生存期(PFS),次要结局为总生存期(OS),在总体子宫内膜癌人群和NSMP亚组中分析。
主要发现
- L1CAM过表达在总体人群PFS HR 3.44(95%CI 2.57-4.59),NSMP亚组PFS HR 3.34(95%CI 2.05-5.44)。
- ER缺失在总体人群PFS HR 3.13(95%CI 2.45-4.00),NSMP亚组PFS HR 3.14(95%CI 2.00-4.91)。
- ARID1A突变在NSMP亚组PFS HR 2.35(95%CI 1.09-5.06),不良预后影响仅限于NSMP。
- β-catenin/CTNNB1和PIK3CA/PTEN突变在两组中均未显示一致的预后意义。
临床怎么用
- 原文结论指出ER缺失和L1CAM过表达可能作为NSMP亚组的预后标志物,支持更个体化的辅助治疗策略。
局限性
- 需进一步研究以明确ARID1A等其他改变在NSMP肿瘤中的预后作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study, we aimed to evaluate the prognostic impact of molecular alterations beyond those included in the Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE), in order to identify biomarkers that could improve prognostic stratification within the No Specific Molecular Profile (NSMP) subgroup of endometrial cancers. METHODS: This systematic review and meta-analysis was conducted according to PRISMA guidelines. We searched PubMed, Scopus and Web of Science for studies published up to December 2024. We included prospective and retrospective studies assessing the prognostic impact of molecular alterations not included in the ProMisE classification, reporting outcomes as hazard ratios (HRs). The primary outcome was progression-free survival (PFS), and the secondary outcome was overall survival (OS), analyzed in both the overall endometrial cancer population and specifically within the NSMP subgroup. RESULTS: A total of 19 studies met the inclusion criteria and were included in the final analysis: 17 retrospective and 2 prospective, all observational in design. L1CAM overexpression and ER loss were identified as unfavorable prognostic factors in the overall endometrial cancer population (PFS HR 3.44 [2.57, 4.59; 95 % CI] and 3.13 [2.45, 4.00; 95 % CI], respectively) and within the NSMP subgroup (PFS HR 3.34 [2.05, 5.44; 95 % CI] and 3.14 [2.00, 4.91; 95 % CI], respectively). ARID1A mutation showed a negative prognostic impact limited to NSMPs (PFS HR 2.35 [1.09, 5.06; 95 % CI]). Conversely, β-catenin/CTNNB1 and PIK3CA/PTEN mutations did not demonstrate consistent prognostic significance in either group. CONCLUSIONS: These findings underscore the potential of ER loss and L1CAM overexpression as prognostic markers within the NSMP subgroup, supporting more personalized adjuvant strategies. Further research is needed to clarify the prognostic role of other alterations, such as ARID1A, specifically within NSMP tumors. PROSPERO registration number: CRD420250654207.
引用
- Marchetti M, Vezzaro T, Carollo M, et al. The challenge of molecular stratification in No Specific Molecular Profile endometrial cancer. Gynecol Oncol. 2025. PMID: 40752272. doi:10.1016/j.ygyno.2025.07.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。